



OPKO Health's BioReference Laboratories





COVID-19 Media Kit

About BioReference Laboratories


BioReference is at the center of progress for patient care, providing testing and related services to physicians, clinics, hospitals, long-term care facilities, employers, government units, correctional institutions and more. We are a diversified commercial laboratory, humanizing and streamlining the process between data and diagnosis. As the largest full-service specialty laboratory, servicing approximately 11 million patients annually, and with a leading position in genetics, women's health and cancer, we are advancing the course of modern medicine.

- Founded in 1981, BioReference is the third largest clinical laboratory in the United States, providing diagnostic services for nearly 40 years
- Contracted with all major national health insurers and hundreds of regional plans
- Experienced medical staff of over 300 M.D.s and Ph.D.s
- Employs more than 4,000 people working across the nation to provide a superior level of healthcare
- Full-service genetics laboratory

BioReference Laboratories, Inc. Overview

<p>Leading National Clinical Laboratory</p>	<p>50,000 Requisitions Daily</p>	<p>4,000 Employees - 300+ Medical Staff</p>	<p>Serving 11 Million Patients Annually</p>	<p>First Class Logistics</p>
				<ul style="list-style-type: none"> • 1.5M+ stops annually • 17M+ miles driven annually • 475+ cars in the fleet • 450+ plus drivers in logistics

Company Timeline



Executive Management



Dr. Jon Cohen

Executive Chairman, BioReference
Senior Vice President, OPKO Health

Dr. Jon R. Cohen has overall responsibility for BioReference Laboratories and GeneDx, in addition to serving as SVP for OPKO Health. With more than 30 years of healthcare experience, he is a seasoned strategic leader with a track record of growing existing business and developing new ventures. Dr. Cohen was recently awarded Crain's New York Business 2020 Notable in Health Care.

Dr. Cohen is well recognized in the diagnostics industry having served for nearly a decade as one of the five executive officers for Quest Diagnostics. Previously, he served as Chief Policy Advisor for Governor David Paterson and for six years as Chief Medical Officer for Northwell Health. In 2010, he was named as one of the nation's top 50 most powerful physician executives by Modern Healthcare.

His 2012 TEDMED, "Why Don't Patients Act Like Consumers?" was recently ranked the #1 TEDMED talk that every healthcare executive needs to watch. Dr. Cohen is a vascular surgeon, having completed his residency in surgery at New York Presbyterian Hospital/Weill Cornell Medical Center and vascular surgery fellowship at the Brigham and Women's Hospital at Harvard Medical School. He has published over 100 peer-reviewed professional articles.

Executive Management Team



Geoff Monk
President



Dr. James Weisberger
M.D., F.A.C.P., F.A.S.C.P.
Chief Medical Officer,
EVP, Laboratory Director



Kevin Feeley
Chief Financial Officer



Natalie Cummins
Chief Commercial Officer



Jane Pine Wood
Chief Legal Officer



Craig Allen
Chief Operating
Officer



Richard Schwabacher
Chief Digital Officer



Cindy Jacke
SVP, Strategic Venture
Services



Greg Cahill
VP, Human Resources



Robert Rossi, Esq.
Chief Compliance &
Privacy Officer



Regina Stewart
SVP, Clinical
Laboratory Operations

BioReference Laboratories, Inc. Brands



GenPath Oncology, founded at BioReference in 2000, provides expertise in cancer diagnostics and offer a comprehensive cancer patient workup from one laboratory. From routine clinical and special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes, GenPath offers oncologists a variety of diagnostic solutions.



GenPath Women's Health is a specialty division offering a complete menu of tests for OB-GYNs and women's health providers. Since its inception in 2005, GenPath Women's Health has risen to become one of the premier specialty labs in the country, including its development of an innovative technology platform for sexually transmitted and other vaginal infections, pan-ethnic carrier testing, hereditary cancer testing, and maternal risk assessment and prenatal diagnosis.



GenPath Urology is a specialty division that offers comprehensive tests and services to help diagnose and manage even the most difficult urologic cases. GenPath is pleased to offer 4Kscore®, a blood test that combines four prostate-specific biomarkers with clinical information to provide a male patient with an accurate and personalized measure of his risk for aggressive prostate cancer.

BioReference Laboratories, Inc. Brands





GeneDx is a world renowned genetic testing laboratory founded in 2000 by scientists from the National Institutes of Health (NIH) to address the needs of patients and clinicians concerned with rare inherited disorders. GeneDx currently offers testing for thousands of genetic conditions, using a variety of cutting-edge sequencing and other methods. GeneDx also offers whole exome and genome sequencing, oligonucleotide microarray-based testing for detecting chromosomal abnormalities, and next-generation sequencing gene panels for testing various forms of inherited cancers, inherited cardiac disorders, metabolic disorders, mitochondrial disorders, neurological disorders, and many other conditions.



4Kscore combines four prostate-specific biomarkers with clinical information to provide a male patient with an accurate and personalized measure of his risk for aggressive prostate cancer. The 4Kscore can be used prior to biopsy, or after a negative biopsy, and can predict the likelihood of cancer spreading to other parts of the body in the next 20 years.

SCARLET

- **According to CDC data, 29% of all office-based physician visits required laboratory testing**
- BioReference is the only national laboratory to offer a fully integrated digital solution, providing convenient, on demand test sample collection to patients, when and where they need it
- About Scarlet:
 - Efficient, convenient and safe to use for physicians and patients
 - Inspiration pulled from what consumers use daily to provide ease of use and ubiquitous services
 - Demonstrates new delivery of health care, meeting the demand of patients and physicians



Logos

BioReference
LABORATORIES
an **OPKO** Health Company

S  A R L E T

GeneD 
an **OPKO** Health Company

4Kscore[®]
OPKO Health

UROLOGY
genpath
an **OPKO** Health Company

ONCOLOGY
genpath
an **OPKO** Health Company

WOMEN'S HEALTH
genpath
an **OPKO** Health Company

BioReference
LABORATORIES
an **OPKO** Health Company

Notable Media Coverage of BioReference

Forbes



TIME

THE WALL STREET
JOURNAL

The Atlantic

The Athletic

[Labs Struggled With Surge in Covid-Testing Demand; How One Made It Through](#) – The Wall Street Journal

[Private Labs Are Fueling a New Coronavirus Testing Crisis](#)

– The Atlantic

[BioReference exec chair talks steps to expand coronavirus testing](#)

– CNBC | Mad Money with Jim Cramer

[A Rapid Covid Test That's Also Accurate? The NFL Says It Has One](#)

– The Wall Street Journal

[BioReference Labs and N.Y. begin drive-thru testing—Here's how it works](#) – CNBC | Power Lunch

[Company Testing NBA Players In Bubble Seeks 'Greater Good'](#)

– Forbes

[Why It's So Hard to Get Coronavirus Testing in the U.S. Right Now](#)

– TIME Magazine

[Thompson: What the Warriors' testing plan is really like, up close and swabbed](#) – The Athletic

BioReference Laboratories' COVID-19 Response

BioReference COVID-19 Response

Serving all 50 states with testing locations in: Elmwood Park, NJ; Melbourne, FL; Gaithersburg, MD; Houston, TX; Burbank, CA

- PCR is being performed out of all laboratories
- Performed approximately 16 million COVID-19 PCR tests to date
- Performed approximately 200,000 COVID-19 rapid, point-of-care tests to date
- Capacity to run 80,000 PCR tests per day
- Operating more mobile PCR collection sites than any other commercial laboratory
- Primary laboratory serving NFL, NBA, NHL, MLS and MLB POC
- Leading provider for school COVID-19 Testing, having performed more than 600,000 tests for faculty and students in New York City, Cleveland and Chicago



COVID-19 Key Announcements

Attended White House's Coronavirus Task Force with Vice President Pence.

Launched nationwide availability of a Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR) assay to aid healthcare providers in quickly and efficiently diagnosing patients.

Partnered with the New York State Department of Health to provide testing for the first public drive-through testing facility on the East Coast, located in New Rochelle, NY, the epicenter for the New York State outbreak.

Collaborated with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide COVID-19 testing to patients across the city's five boroughs.

Collaborated with the State of New Jersey to provide COVID-19 testing across the state.

Collaborated with the City of Detroit and City of Miami to provide COVID-19 testing.

Launched nationwide availability of antibody blood tests to detect an immune response after infection with the COVID-19 virus.

Announced continued prioritization of COVID-19 testing for hospital inpatients and critically ill patients around the country, with more than 4,000,000 patients tested to date.

Increased laboratory testing capacity to ensure patients and providers have greater access to testing – currently can accommodate in excess of 60,000 COVID-19 tests per day.

Selected by Major League Soccer, the National Basketball Association and the National Football League to provide COVID-19 testing to players and staff.

Awarded commercial surge capacity testing for COVID-19 emergency response contract by Centers for Disease Control and Prevention.

Through a strategic collaboration with NYC and NYC Health + Hospitals, BioReference performed COVID-19 testing for NYC school principals, teachers and staff members.

BioReference's COVID-19 Response Metrics

Total
Announcements
Year-to-Date*



22

*Release Status

19 Crossed the wire



3 Media advisories

Brand Mentions



13,000

Share of Voice Overtime



■ Positive ■ Negative ■ Neutral

Aggregate Readership



19 billion

COVID-19 Fact Sheets

COVID-19 Response Summary:

<https://bioreference.corpcomm.com/PDFs/bioreference/201311.pdf?v=08122020151635>

RT-PCR COVID-19 Physician Brochure:

<https://bioreference.corpcomm.com/PDFs/bioreference/201307.pdf?v=08122020152104>

Patient Brochure for COVID-19 Testing:

https://www.bioreference.com/wp-content/uploads/2020/04/201277_Coronavirus-Patient-Brochure-1.pdf

Patient Information for Antibody Testing:

https://www.bioreference.com/wp-content/uploads/2020/05/201346_Coronavirus-Antibody-Testing-Patient-Sheet.pdf


Physician Resource for Antibody Testing for COVID-19:

https://www.bioreference.com/wp-content/uploads/2020/05/201345_Coronavirus-Serum-Physician-Sheet.pdf

Employer/Government Antibody Resource:

<https://www.bioreference.com/wp-content/uploads/2020/05/201367.pdf>

Available Getty Images



BioReference
LABORATORIES
an OPKO Health Company

Sports and Entertainment Gallery



Looking Forward

- Many factors continue to drive demand for COVID-19 testing at BioReference Laboratories.
 - Hospitals desire more PCR testing for patients undergoing elective in-patient and outpatient procedures.
 - Hospitals will continue to test their employees for both PCR and antibody presence.
 - Physicians will continue to test their patients for COVID-19 disease.
 - The general public continues to desire to know their antibody status.
- The return of the flu season this fall and winter may have an impact on COVID-19 testing and other respiratory infection testing.
- Employers are working through their strategies for employees to return to work which includes both PCR and antibody testing programs.

Contact Information

Hillary Titus

Corporate Communications

BIOREFERENCE LABORATORIES

481 Edward H. Ross Drive, Elmwood Park, NJ 07407

M 201.406.9968

E htitus@bioreference.com